The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
October 21st 2024
Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
IVF, Assisted Reproduction Techiques Linked to Increased Gestational Diabetes
September 19th 2019A new meta-analysis presented at EASD 2019 found that women who gave birth following use of assisted reproductive techniques had a 53% increased risk of gestational diabetes compared to women who conceived naturally.
DAPA-HF Reveals Reduced Death, Hospitalizations from HF with Dapagliflozin
September 1st 2019Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.
Trial Shows Metformin with Liraglutide Promising for Children with Type 2 Diabetes
August 21st 2019Metformin as monotherapy is the preferred treatment for children and teens with type 2 diabetes, but a new study published in the Aug. 15 issue of the New England Journal of Medicine suggests that adding liraglutide to the treatment can more effectively control glycemic levels.
Stroke Treatment Without Thrombolytic Therapy, New Research
August 14th 2019Stimulating the sphenopalatine ganglion-a collection of nerve cells closely associated with the trigeminal nerve most responsible for headaches-could be a safe intervention for patients with acute ischemic stroke who aren’t eligible for thrombolytic therapy, researchers report in The Lancet.
U.S. Ranks High in Hypertension Awareness, Treatment and Control
August 14th 2019Awareness of the prevalence of hypertension has increased substantially over the past 40 years in high-income countries, as has treatment and control of the condition. But, the level of control falls short of rates seen in dedicated hypertension programs, and it’s stagnating, according to research published last month in The Lancet.
FDA Decision on Icosapent sNDA Delayed for Advisory Committee Meeting
August 9th 2019The committee meeting, tentatively scheduled for November 14, will have to precede the sNDA PDUFA action date set to review the drug's potential indication for reducing residual cardiovascular risks in patients with elevated triglycerides.